| 6.08 Data as of Jun 18 |  0.00 / 0.00%Today’s Change | 5.85 Today|||52-Week Range 6.45 | -- Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP -- |
Company Description
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company engaged in discovering and developing innovative, proprietary pharmaceutical drugs and diagnostic products to identify, treat, and prevent a broad range of human diseases including metabolic disorders, eye disease, kidney disease, acute and chronic inflammation, and male sexual dysfunction. The company intends to develop proprietary pharmaceutical drugs and diagnostic products which capitalize on its intellectual property, which includes owned and assigned patents, filed patent applications, exclusive licenses, and trade secrets and know-how, some of which may be the subject of future patent applications. Its intellectual property focuses on three primary areas: new indications for previously approved drugs, New Molecular Entities, and rapid point-of-care tests for diagnosis, monitoring and screening. Ampio was founded by David Bar-Or and Michael Macaluso on December 18, 2008 and is headquartered in Greenwood Village, CO.
Employees
Shareholders
| Mutual fund holders | 6.23% |
| Individual stakeholders | 16.00% |
| Other institutional | 14.78% |
Top Executives
| Michael Macaluso, MBA | Chairman & Chief Executive Officer |
| Joshua Disbrow, MBA | Chief Operating Officer |
| Mark D. McGregor, CPA | Chief Financial Officer & Secretary |
| David Bar-Or, MD | Director & Chief Scientific Officer |
| Vaughan Lennox Clift, MD | Chief Regulatory Affairs Officer |
.
